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ABSTRACT
Treatment of glioblastoma xenografts with chloroquine results in macroautophagy/autophagy inhibi-
tion, resulting in a reduction of tumor hypoxia and sensitization to radiation. Preclinical data show that 
EGFRvIII-expressing glioblastoma may benefit most from chloroquine because of autophagy depen-
dency. This study is the first to explore the safety, pharmacokinetics and maximum tolerated dose of 
chloroquine in combination with radiotherapy and concurrent daily temozolomide in patients with 
a newly diagnosed glioblastoma. This study is a single-center, open-label, dose-finding phase I trial. 
Patients received oral chloroquine daily starting one week before the course of chemoradiation (temo-
zolomide 75 mg/m2/d) until the end of radiotherapy (59.4 Gy/33 fractions). Thirteen patients were 
included in the study (n = 6: 200 mg, n = 3: 300 mg, n = 4: 400 mg chloroquine). A total of 44 adverse 
events, possibly related to chloroquine, were registered including electrocardiogram QTc prolongation, 
irreversible blurred vision and nausea/vomiting resulting in cessation of temozolomide or delay of 
adjuvant cycles. The maximum tolerated dose was 200 mg chloroquine. Median overall survival was 
16 months (range 2–32). Median survival was 11.5 months for EGFRvIII- patients and 20 months for 
EGFRvIII+ patients. A daily dose of 200 mg chloroquine was determined to be the maximum tolerated 
dose when combined with radiotherapy and concurrent temozolomide for newly diagnosed glioblas-
toma. Favorable toxicity and promising overall survival support further clinical studies.
Abbreviations: AE: adverse events; CQ: chloroquine; DLT: dose-limiting toxicities; EGFR: epidermal 
growth factor receptor; GBM: glioblastoma; HCQ: hydroxychloroquine; IDH1/2: isocitrate dehydrogenase 
(NADP(+)) 1/2; MTD: maximum tolerated dose; CTC: National Cancer Institute Common Toxicity Criteria; 
MGMT: O-6-methylguanine-DNA methyltransferase; OS: overall survival; po qd: per os quaque die; SAE: 
serious adverse events; TMZ: temozolomide; WHO: World Health Organization
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Glioblastoma (GBM) is the most common malignant primary 
brain tumor with an estimated incidence of 4.27 per 100.000 
in Europe [1]. Despite extensive surgery, radiotherapy and 
temozolomide (TMZ), the prognosis remains poor with 
a median overall survival (OS) of approximately 15 months 
and a five-year OS of 5–10% [2]. None of the attempts to 
improve the prognosis, including radiation dose escalation, 
targeted agents and immunotherapy, have changed the dismal 
outlook [3]. GBM are known to be one of the most hetero-
geneous tumors in humans with both major inter- and intra-
tumoral variation [4]. Molecular biomarkers such as MGMT 
(O-6-methylguanine-DNA methyltransferase) promotor 
methylation, 1p/19q co-deletion and IDH1/2 (isocitrate dehy-
drogenase (NADP(+)) 1/2) mutation significantly predict 
patient survival [5]. EGFRvIII (epidermal growth factor recep-
tor mutation type III) expression, a genotype observed in 
50–60% in tumors with amplification of the EGFR gene, is 
associated with a poor prognosis [6–8]. This is in part through 
enhanced repair of DNA double-strand breaks and an ele-
vated hypoxic fraction [9,10]. Tissue hypoxia has been shown 
to correlate with enhanced tumor cell invasion and poor out-
come, independent of treatment modality [11].
Macroautophagy (hereafter described as “autophagy”) is 
a lysosomal degradation pathway, which allows the cell to 
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recycle amino acids and other nutrients to maintain energy 
levels, protein synthesis and essential metabolic processes 
during hypoxic conditions and metabolic stress [12]. During 
this process, a double-membrane structure is formed in which 
cellular content is engulfed (autophagosome). The autophago-
some fuses with a lysosome to expose its content to the 
lysosomal degradative enzymes. Resistance to autophagy is 
one of the major reasons why GBM stem cells are known to 
be highly resistant to both radiotherapy and chemotherapy 
[13–16]. In EGFRvIII-mutated tumors, autophagy is essential 
to maintain a viable hypoxic fraction and, when targeted, 
results in elevated response of the tumor to irradiation [10].
The lysosomotropic drug chloroquine (CQ) is 
a 4-aminoquinoline commonly used for the prophylaxis and 
treatment of malaria, rheumatoid arthritis, liver amoebiasis, 
sarcoidosis and lupus erythematodes. CQ accumulates in the 
lysosome and thereby raises the intralysosomal pH, prevent-
ing the autophagosome-lysosome fusion essential for autop-
hagy [17,18]. There is mounting pre-clinical evidence that 
hypoxic cells depend on autophagy for survival and that 
inhibiting autophagy with CQ can enhance both radiotherapy 
and chemotherapy cytotoxicity in GBM [19–22]. Moreover, 
there is evidence that CQ reduces tumor hypoxia by improv-
ing the structural and functional features of the intratumoral 
blood vessels through vessel normalization via NOTCH1 sig-
naling [23]. CQ can penetrate into the central nervous system 
and the potential added value of CQ has been demonstrated 
in a small randomized controlled trial in GBM treated with 
radiotherapy and carmustine, which showed a trend toward 
increased OS [24]. Based on these pre-clinical and early clin-
ical results CQ has received an orphan drug designation for 
the treatment of glioma in the EU in November 2014 (EU/3/ 
14/1377) and the US in May 2015 (Request number: 
15–4750). We propose that combining CQ with radiotherapy 
and TMZ might increase OS significantly. Taking into 
account that the intracellular effects of CQ are potentially 
dose-dependent and the effects of CQ in combination with 
TMZ have not yet been investigated, the recommended phase 
two dose of CQ in combination with radiotherapy and TMZ 
needs to be established. This phase I study explores the safety, 
pharmacokinetics and maximum tolerated dose (MTD) of CQ 
in combination with radiotherapy and daily TMZ in patients 
with a newly diagnosed GBM.
Results
Thirteen patients were enrolled in the study between 
August 2016 and December 2018. The patient and tumor 
characteristics are summarized in Table 1.
The adverse events ≥ CTCAE grade II are presented in 
Table 2. Fatigue and nausea were the most common reported 
side effects. No toxic deaths occurred. One patient died due to 
a thrombotic event shortly after chemoradiation, which was 
considered unlikely due to CQ. All patients with reported 
toxicities related to study treatment recovered except for one 
patient with blurred vision. In 8 patients, eleven Serious 
Adverse Events (SAE) were reported (Table 3), of which 5 
were considered unlikely or not related to CQ. One patient 
was admitted to the emergency department after a seizure. 
During hospitalization, he sustained a minor head injury after 
a fall, which was possibly caused by an increased sedative 
effect of midazolam after co-administration with CQ, due to 
reduced metabolism through CYP/cytochrome P450.
At a daily dose of 400 mg CQ, 3 out of 4 patients experi-
enced a DLT, after which the study medication was discon-
tinued. In the final week of study treatment, two patients 
showed a significant prolongation of the electrocardiogram 
QT corrected interval (CTCAE grade III). The QT-corrected 
interval recovered to normal within 1 week after cessation of 
CQ in one patient but required four weeks to recover for the 
other. Neither of the two patients experienced any physical 
complaints due to the cardiac conduction disturbances. 
Another patient in the 400 mg CQ cohort developed blurred 
vision in the second week of chemo-radiation. Ophthalmic 
examination showed no abnormalities. As an adverse effect 
from CQ could not be excluded, CQ was stopped. The vision 
did not recover after cessation of CQ at the end of follow-up 
9 months after inclusion. At a daily dose of 300 mg CQ, 2 
patients experienced CTCAE grade II and III nausea and 
vomiting, which resulted in hospital admission in one patient 
and discontinuation of TMZ in both and was therefore con-
sidered a DLT in both cases. At a daily dose of 200 mg CQ, 1 
patient developed nausea, vomiting and liver function 
abnormalities resulting in hospital admission, which was 
Table 1. Patient and tumor characteristics. Methylation of the MGMT 
(O-6-methylguanine-DNA methyltransferase) promoter, IDH1/2 (isocitrate dehy-
drogenase (NADP(+)) 1/2) mutation, loss of heterozygosity of 1p and 19q (1p/ 
19q co-deletion), EGFRvIII (epidermal growth factor receptor, mutation type III). 
Amount of expression detected: negative (-), less than 1% (+), between 1% and 
60% (++) or more than 60% (+++) of the cells positive; World Health 
Organization (WHO) Performance status.
Patient characteristics
Age [years]












MGMT promotor methylation 5 (38%)
IDH1/2 mutation
IDH 1 1 (8%)
IDH 2 0 (0%)






Methylation of the MGMT (O-6-methylguanine-DNA methyltransferase) promo-
ter, IDH1/2 (isocitrate dehydrogenase (NADP(+)) 1/2) mutation, loss of hetero-
zygosity of 1p and 19q (1p/19q co-deletion), EGFRvIII (epidermal growth factor 
receptor, mutation type III). Amount of expression detected: negative (-), less 
than 1% (+), between 1% and 60% (++) or more than 60% (+++) of the cells 
positive; World Health Organization (WHO) Performance status. 
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considered a DLT. A daily dosage of 200 mg CQ was therefore 
considered the MTD.
Valid pharmacokinetic measurements were available from 
the 200–300 mg cohorts. Median duration of CQ exposure 
was 52 d. Median CQ plasma concentrations at the expected 
steady-state (after 2 weeks of CQ) were 192.3 μg/L (200 mg 
CQ) and 391.9 μg/L (300 mg CQ). At the end of radiotherapy, 
median CQ plasma concentrations were 199.5 μg/L (200 mg 
CQ) and 482.4 μg/L (300 mg CQ).
Adherence to the study medication was high, with only 2 
patients missing 3 and 6 dosages of CQ, respectively. At data 
cutoff (February 2020), 1 patient had discontinued treatment 
including chemoradiation at his own request in the first week 
of treatment due to complaints of nausea and vomiting, with-
out the use of anti-emetics. This patient was replaced by 
another patient, after which follow-up ended. No other 
patients were lost to follow-up. One patient misunderstood 
the instructions regarding TMZ and only took it during 
weekdays.
At the time of analysis, the median follow-up was 
32 months. The median OS was 16 months, 95% CI [6.5–25.5] 
(Figure 1). The median OS time was 21 months, 95% CI 
[12.5 −29.5], for patients with an MGMT methylated promo-
ter and 12.5 months, 95% CI [8.9–16.1], for patients with an 
unmethylated promoter. An EGFRvIII mutation was present 
in 7 out of 13 patients. These patients had a median OS of 
20 months, 95% CI [13.6–26.4], compared to 11.5 months, 
95% CI [9.1–13.9], in non-EGFRvIII-mutated patients 
(Figure 2).
Discussion
Pre-clinical evidence has shown that patients with a GBM 
may benefit from adding CQ to chemoradiation, resulting in 
autophagy inhibition and thereby sensitizing tumor treat-
ment. This phase I dose-escalation trial was conducted to 
evaluate the safety of CQ when combined with radiotherapy 
and TMZ. This trial is the first to show that co-administration 
of CQ in combination with radiotherapy and TMZ is feasible. 
We have established 200 mg CQ daily as the recommended 
phase two dose in combination with chemoradiation in GBM.
Although CQ is administered in multiple conditions, and 
the side effect profile is well established, a significant number 
of adverse events were observed in this trial. At 400 mg CQ, 
DLTs included grade III blurred vision and grade III ECG 
QT-corrected interval prolongation. The complaints of severe 
blurred vision developed after a cumulative dose of 7.2 g. 
Retinopathy could not be objectified with ophthalmological 
examination. Retinal toxicity is a well-known complication 
due to CQ and its derivatives, which usually occurs at high 
daily doses, taken to high cumulative doses for a prolonged 
period of ingestion (years) [25]. Cardiac conduction distur-
bances, including QT-corrected interval prolongation, are also 
a recognized adverse effect of CQ-use. Risk factors for cardi-
otoxicity include renal insufficiency, older age, preexisting 
cardiac disease, elevated per-kilogram daily dose and 
Table 2. Adverse events grade II–V. Events are listed in alphabetical order and 
were graded according to National Cancer Institute Common Terminology 
Criteria for Adverse Events (version 4.03) grade criteria. All counts represent 
a patient; multiple occurrences of the same adverse event in one individual are 



















Blurred vision 1 1 Probably
Confusion 1 Unrelated




ECG QT corrected interval 
prolonged
1 2 Possibly/ 
Probably
Facial nerve disorder 1 Unrelated
Fall (Trauma capitis) 1 Possibly





Nausea 4 2 Possibly





Rash maculo-papular 1 Possibly
Seizure 1 Unrelated
Thrombolic event 1 1 Unlikely
Vomiting 1 Possibly
Weight loss 1 Probably
Wound complication, non 
infectious
1 Unrelated
Events are listed in alphabetical order and were graded according to National 
Cancer Institute Common Terminology Criteria for Adverse Events (version 
4.03) grade criteria. All counts represent a patient; multiple occurrences of 
the same adverse event in one individual are counted only once at the highest 
grade. All grade 2–5 events are shown. 
Table 3. Serious adverse events. Serious Adverse Events (SAEs) presented per 
cohort CQ. The adverse events were graded according to National Cancer 







200 Confusion III Unrelated No adjuvant 
temozolomide











Diarrhea III Possibly i.v. fluids
Nausea III Possibly Stop chloroquine
Vomiting III Possibly Stop chloroquine
300 Nausea III Possibly Stop chloroquine 
Stop temozolomide 
Stop radiotherapy
400 Hypercalcemia II Unlikely i.v. fluids/ 
bisphosphonates
Blurred vision III Probably Stop chloroquine
Hallucinations IV Unrelated Haloperidol
Serious Adverse Events (SAEs) presented per cohort CQ. The adverse events were 
graded according to National Cancer Institute Common Terminology Criteria 
for Adverse Events (CTCAE version 4.03). 
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prolonged CQ treatment [26]. Neither of the patients had 
prior cardiac disease or renal insufficiency and therefore the 
only risk factor was an elevated CQ-dose. Nausea and vomit-
ing have been well-established side effects of CQ. Moreover, 
the tumor, postoperative complications and the chemoradia-
tion may have aggravated these complaints.
Several other groups have published clinical trials adding 
CQ to glioma treatment. Bilger et al treated 5 patients with 
Figure 1. Kaplan-Meier analysis of overall survival of the complete study cohort. Median overall survival is presented by the dotted line.
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a recurrent GBM with 250 mg CQ daily and re-irradiation 
without TMZ, which was well-tolerated and no CQ-related 
toxicity was observed [27]. Sotelo et al. combined CQ (150 mg 
po qd) with radiotherapy and carmustine after surgery [24]. 
In this single-center trial, 30 patients receiving surgery, che-
motherapy and radiotherapy were randomized to receive CQ 
or placebo for 12 months. The median OS was 24 months for 
the CQ-treated patients and 11 months for controls. No 
Figure 2. Kaplan-Meier analysis of overall survival split by EGFRvIII amplification status (present or absent). Median overall survival of both groups is presented by the 
dotted line.
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significant CQ-related toxicity was observed. The difference in 
survival time was statistically significant when compared to 
control subjects in their later published institutional experi-
ence [28]. Rosenfeld et al published a phase I–II trial in which 
resected GBM patients received the CQ derivative hydroxy-
chloroquine (HCQ) in doses of 200–800 mg po qd with 
radiation therapy and concurrent TMZ followed by adjuvant 
TMZ [29]. Pharmacokinetic analysis showed a significant 
therapy-associated increase in autophagic vacuoles and LC3B 
in the peripheral blood mononuclear cells, which was corre-
lated with higher HCQ exposure. The MTD was found to be 
600 mg HCQ po qd as sustained hematological toxicity pre-
vented further dose escalation. When comparing the clinical 
outcome to historical data, the OS was not significantly dif-
ferent. HCQ was preferred over CQ based on a more favor-
able toxicity profile with a lower risk of retinopathy and 
cardiotoxicity. This is reflected in the significantly higher 
MTD in comparison to the MTD of 200 mg CQ found in 
this study. However, the authors could not exclude the possi-
bility that the combination of CQ with radiotherapy and TMZ 
would have been more potent, as CQ crosses the blood-brain 
barrier more easily and can potentially accumulate in brain 
tissue to a higher level than the blood plasma concentra-
tion [30].
In addition to glioma, CQ is currently being investigated in 
a wide range of cancer types, with 3 studies currently recruit-
ing including a large phase III trial in glioma (NCT03243461) 
(clinicaltrials.gov). In a phase I study, the combination of 
300 mg CQ per day with gemcitabine in patients with meta-
static or unresectable pancreatic cancer was well-tolerated 
[31]. A recent randomized window-of-opportunity trial in 
breast cancer patients has evaluated single-agent 500 mg CQ 
per day in a preoperative setting [32]. No significant effect of 
CQ on tumor proliferation was established. Nearly 15% of 
patients discontinued treatment due to adverse events, mainly 
nausea and/or abdominal cramps.
Induction of autophagy by radiation and TMZ results in 
radioresistance of glioma stem cells, which can be inhibited 
with CQ [13,21,33–35]. Several studies have demonstrated 
that inhibition of autophagy caused by radiotherapy and 
TMZ can ameliorate apoptosis in GBM cells and thereby 
increase therapeutic outcome [20,36–38]. There is evidence 
that CQ exerts its therapeutic effects also by autophagy- 
independent mechanisms such as promotion of lysosomal 
membrane permeabilization inducing apoptosis [39,40] and 
tumor vessel normalization [23]. Autophagy has been 
described as an important regulator of cellular immune 
response, inhibiting the tumor-specific immune response 
through suppression of ATP release attracting dendritic 
cells and T-lymphocytes [41,42]. Moreover, it can lead to 
accumulation TLR4 (toll like receptor 4) on the cell surface, 
thereby increasing the tumor-specific immune response 
[43,44].
EGFRvIII is a potential predictive biomarker for the addi-
tion of CQ to concurrent chemoradiation. Even though 
a formal statistical analysis was not possible, Figure 2 shows 
that CQ may increase OS in EGFRvIII-positive tumors. 
Overexpression of EGFRvIII has been shown to increase cell 
proliferation and survival under stress conditions such as 
hypoxia or nutrient deprivation by an increase in autophagic 
activity [9,45,46]. A retrospective analysis of patients with 
a GBM treated with radiotherapy and carmustine demon-
strated that the addition of CQ improved OS from 5 to 
10 months in the EGFRvIII-negative GBM and improved 
survival from 3 to 15 months in the EGFRvIII-positive 
GBM [10].
Although the pharmacokinetic properties of CQ alone are 
known, the pharmacokinetic properties of CQ in combination 
with TMZ have not yet been investigated. The required dose 
for autophagy inhibition has not yet been established. The 
trough level was chosen as it is directly measurable and the 
most reliable assessment of the CQ plasma concentration. The 
CQ plasma T1/2 is ca 2 weeks, meaning a steady-state plasma 
concentration was expected to be reached in the second week 
of chemoradiation. In this trial, a near steady-state was 
observed after 2 weeks (data not shown). Rosenfeld et al 
have previously demonstrated a dose-dependent increase in 
autophagy inhibition for HCQ [29]. Although we did not 
reach the planned 600 mg CQ dose level in this study, phar-
macokinetic studies have shown that patients will reach 
a steady-state concentration of approximately 10 μM CQ 
with a daily intake of 250 mg, which has been shown to be 
an effective dose for autophagy inhibition [36,47]. Yet other 
studies suggest that higher doses of CQ are required for 
a therapeutic effect [48,49]. This possibly explains an apparent 
lack of effect on OS in our overall patient cohort.
This study has several limitations. Although this study’s 
traditional 3 + 3 design is considered safe, it does have several 
disadvantages, e.g., the low likelihood of selecting the true 
MTD due to pre-defined dose levels, uncertainty in detecting 
all DLTs because of low patient numbers and no option to re- 
escalate the CQ dose. CQ concentrations vary significantly 
between different types of tissue, e.g., CQ accumulates in red 
blood cells, and the concentration within red blood cells may 
be > 4–10 x higher than the plasma concentration [50]. 
However, the serum fraction of CQ is in direct contact with 
the possible target tissue. Therefore, we hypothesize this con-
centration to be more relevant with regards to both the effects 
and side effects of CQ, and therefore chose to quantify CQ 
based on serum concentration. This should be further inves-
tigated in future trials. CQ was initiated one week before the 
start of chemo- and radiotherapy in order to reach a steady- 
state early into treatment. However, it is unclear if a steady 
state is necessary to reach optimal autophagy inhibition. 
Unlike previous clinical trials [24,29], CQ was stopped at the 
end of concurrent chemoradiation in order to avoid potential 
long-term toxicity caused by CQ’s extensive plasma terminal 
elimination half-life of 40–60 d and its active metabolites. We, 
however, cannot exclude that CQ concurrent to the adjuvant 
cycles of TMZ is a more effective combination. Further 
research into the timing of adjuvant CQ at the time of che-
motherapy resistance is necessary [19]. LC3B-II within per-
ipheral blood mononuclear cells currently serves as 
a surrogate to measure the inhibitory effect of CQ in tumor 
cells [51]. There currently is no technique available to directly 
measure autophagy inhibition within the tumor. Further 
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development of a biomarker or tracer to evaluate autophagy 
inhibition is highly desirable to evaluate the clinical effect 
in vivo.
In conclusion, this study has shown that despite CQ’s well- 
known toxicity profile, it may still elicit significant adverse 
effects in combination with TMZ and radiotherapy in doses 
commonly described for rheumatoid arthritis. It is anticipated 
that more potent and less toxic autophagy inhibitors such as 
Lys05 or Verteporfin will become clinically available through-
out the years to come, but these are currently still under 
investigation in preclinical models. Combination treatment 
with autophagy inhibitors has the potential to become the 
new standard of care for GBM as it may significantly impact 
survival, especially for a subset of patients.
Materials and methods
Eligibility
The main inclusion criteria were histologically confirmed 
newly diagnosed GBM, age 18–70 y/o and a World Health 
Organization (WHO) performance status ≥ 2. The blood 
samples of these patients required a neutrophil count of ≥ 
1.5 x 109/L, platelets ≥ 100 x 109/L, a serum creatinine ≤1.5 
x upper limit of normal, total bilirubin ≤ 1.5 x upper limit of 
normal and GPT/alanine transaminase or GOT1/aspartate 
aminotransferase and ALPL/alkaline phosphatase ≤3 x upper 
limit of normal. The main exclusion criteria included prior 
radio- or chemotherapy, recent severe cardiac disease, 
a history of cardiac arrhythmia, cardiac conduction distur-
bances or medication potentially causing them, retinal or 
visual field changes unrelated to the tumor location and the 
use of concurrent CYP/cytochrome P450 enzyme-inducing 
drugs.
Study design
This study was a single-center, open-label, dose-finding phase 
I trial. Eligible patients received radiotherapy and TMZ (Sun 
Pharmaceutical Industries Ltd, 15913384) according to the 
standard clinical protocol. This consists of 33 daily fractions 
of 1.8 Gy to the tumor which included the region of enhance-
ment plus the resection cavity (if resected) with a 2 cm margin 
on magnetic resonance imaging in combination with TMZ 
75 mg/m2 per os quaque die (po qd) and six adjuvant cycles of 
TMZ 150–200 mg/m2 po qd. CQ (Basic Pharma 
Manufacturing B.V, IMP10153) was taken daily starting one 
week before the start of chemo-radiation and ending on the 
last day of radiotherapy. CQ was initially planned to be 
escalated in 3 dose-levels (200 mg, 400 mg and 600 mg po 
qd), each dose level containing a minimum of 3 and 
a maximum of 6 patients (3 + 3 design) [52]. Adverse events 
(AEs) were assessed using the National Cancer Institute 
Common Toxicity Criteria (CTC) version 4.03. Dose- 
limiting toxicities (DLTs) were defined as an absolute neutro-
phil count ≤ 500/µL for 7 d; febrile neutropenia (neutrophil 
count less than 500 cells per microliter and fever of ≥ 38.5°C); 
any grade 4 thrombocytopenia (< 25 x 109/L), and/or requir-
ing platelet transfusion or bleeding requiring medical 
intervention; any ≥ grade 3 non-hematological toxicity except 
fatigue, nausea, fever or skin reactions; interruption of radio-
therapy or TMZ due to toxicity during concurrent chemo- 
radiation or delay of adjuvant cycles of TMZ. Toxicity was 
considered a DLT if it was at least possibly related to CQ. If 
DLT was observed in one out of three initial patients, an 
additional 3 patients were enrolled at that dose level. In case 
more than one out of the initial three had DLT, no additional 
patients were required. The MTD for CQ was defined as one 
dose level below that at which two or more patients experi-
enced a DLT, or if no DLTs were observed, the highest 
evaluated dose. Once the recommended phase two dose was 
identified, 3 additional patients were enrolled in order to 
confirm treatment tolerability. Safety was assessed by an 
independent data safety monitoring committee four weeks 
after treatment of every third subject.
Study assessments
Baseline assessment included a history and physical examina-
tion, WHO performance status, laboratory analysis, electro-
cardiogram, ophthalmological examination and a tone 
audiogram. Laboratory analyses were performed weekly dur-
ing concurrent treatment and monthly thereafter. An electro-
cardiogram was repeated in the second and final week of 
study treatment for the first 7 patients. The protocol was 
amended to weekly ECG surveillance during CQ-treatment 
for the remainder of patients due to observed toxicity. 
Ophthalmological examination and a tone audiogram were 
repeated 4 weeks after the end-of-study treatment and if 
clinically indicated. Assessment of adverse events and physical 
and neurological examinations were performed monthly dur-
ing the adjuvant cycles of TMZ. The blood concentration of 
CQ was monitored on four time points throughout the regi-
men and before the adjuvant cycles of TMZ (first and second 
week and end of chemoradiation and 4 weeks after chemor-
adiation). CQ was analyzed in serum samples using validated 
liquid chromatography coupled with tandem mass spectro-
metry (LC-MS/MS) method. The chromatographic separation 
was achieved on a reversed-phase Thermo Fisher Scientific 
Hypurity C18 (50x2.1 mm, 3μ) column (22103–052130), with 
gradient elution using ammonium formate 0.02 mol/L pH 3.5 
and methanol as mobile phase at a flow rate of 0.5 mL/min. 
Protein precipitation with 10% trichloroacetic acid and D4- 
CQ was utilized for extraction of CQ from the matrix. CQ was 
quantitated using MS/MS detection with an electrospray ioni-
zation source in positive multiple reaction monitoring (MRM) 
mode. The MS/MS response was linear over a concentration 
range from 10 to 2000 μg/L with a correlation coefficient (R2) 
of 0.999 or better. The within- and between-day precision (% 
relative standard deviation) and accuracy were within the 
acceptable limits as per EMA and FDA guidelines [53,54]. 
Profile parameters included blood trough level, Area Under 
the Curve and elimination half-life. Magnetic resonance ima-
ging was performed within 72 h after brain tumor surgery and 
at least within 6 weeks prior to registration. Follow-up ima-
ging was performed according to standard clinical protocol on 
a three-monthly basis after treatment.
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Molecular profiling
IDH1 or IDH2 mutations were detected with polymerase 
chain reaction and pyrosequencing, MGMT promoter methy-
lation status was analyzed by bisulfite treatment and methyla-
tion-specific polymerase chain reaction followed by 
pyrosequencing. FISH analysis of 1p/19q status was per-
formed using the LSI 1p36/1q25 and 19q13/19p13 FISH 
Probe kit (Abbott Molecular Inc., 04N60-020). To determine 
EGFRvIII expression, formalin-fixed paraffin-embedded biop-
sies were probed with antibodies directed against EGFRvIII 
(clone L8A4, absolute antibody, Ab00184-1.1.) and visualized 
using HRP-linked anti-mouse (Cell Signaling Technology, 
7076S) antibodies) in combination with DAB-staining. 
Tumor biopsies were scored either negative, less than 1% 
(+), between 1% and 60% (++) or more than 60% (+++) of 
the cells positive in EGFRvIII-expression.
Statistical analysis
The primary objective of the study was to determine the 
recommended phase two dose. Secondary objectives included 
evaluation of safety, tolerability, pharmacokinetics and preli-
minary changes in treatment efficacy. All evaluable patients 
were included in the analyses. Analysis was limited to pre-
sentation of descriptive statistics (e.g., median and range) and 
frequencies in cross-tabs. Statistical analysis was performed 
using the statistical program SPSS for Windows (version 22. 
0.0, 2013) and R Statistical Software (version 4.0.1). OS was 
defined as the time from enrollment until death. The survival 
analyses were performed using the Kaplan–Meier method.
The study was approved by the Medical Review Ethics 
Committee at Maastricht University Medical Center +. All 
procedures performed were in accordance with the ethical 
standards of the institutional and/or national research com-
mittee and with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards. Informed con-
sent was obtained from all individual participants included in 
the study. This trial is registered on clinicaltrials.gov 
(NCT02378532).
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